Rule 2.7, 3.10.3, 3.10.4, 3.10.5

Appendix 3B

New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 01/07/96 Origin: Appendix 5 Amended 01/07/98, 01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/12, 04/03/13

Name of entity	of entity
----------------	-----------

APIAM ANIMAL HEALTH LIMITED (the Company)				
ACN	1			
604 961 024				

We (the entity) give ASX the following information.

Part 1 - All issues

You must complete the relevant sections (attach sheets if there is not enough space).

+Class of +securities issued or to be issued

Fully paid ordinary shares (Shares)

Number of *securities issued or to be issued (if known) or maximum number which may be issued 338,450 fully paid ordinary shares

3 Principal terms of the *securities (e.g. if options, exercise price and expiry date; if partly paid *securities, the amount outstanding and due dates for payment; if *convertible securities, the conversion price and dates for conversion)

Fully paid ordinary shares

4 Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities?

If the additional *securities do not rank equally, please state:

- the date from which they do
- the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment
- the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment

The Shares will be quoted and will rank equally with all other ordinary shares on issue in the Company.

04/03/2013 Appendix 3B Page 1

⁺ See chapter 19 for defined terms.

5	Issue price or consideration	The Shares are issued at \$0.7998 per Share
6	Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets)	The Shares are issued to participating shareholders under the Company's Dividend Reinvestment Plan in relation to the Company's 2018 interim dividend, as announced to the ASX on 26 February 2018.
6a	Is the entity an +eligible entity that has obtained security holder approval under rule 7.1A? If Yes, complete sections 6b – 6h in	No
	relation to the *securities the subject of this Appendix 3B, and comply with section 6i	
6b	The date the security holder resolution under rule 7.1A was passed	N/A
6c	Number of *securities issued without security holder approval under rule 7.1	N/A
6d	Number of *securities issued with security holder approval under rule 7.1A	N/A
6e	Number of *securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)	N/A
6f	Number of *securities issued under an exception in rule 7.2	338,450 Shares are issued under Exception 7 of ASX Listing Rule 7.2
6g	If *securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the *issue date and both values. Include the source of the VWAP calculation.	N/A
6h	If *securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements	N/A
6i	Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements	See Annexure 1

7	+Issue	dates

Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A.

Cross reference: item 33 of Appendix 3B.

27 April 2	018		

8 Number and *class of all *securities quoted on ASX (including the *securities in section 2 if applicable)

Number	+Class
100,619,197	Fully paid ordinary Shares
1,131,647	Fully paid ordinary Shares escrowed until 1 September 2018
292,008	Fully paid ordinary Shares escrowed until 1 November 2018
219,537	Fully paid ordinary Shares escrowed until 5 January 2019
292,005	Fully paid ordinary Shares escrowed until 1 November 2019
129,103	Fully paid ordinary Shares escrowed until 19 March 2019
129,102	Fully paid ordinary Shares escrowed until 19 March 2020

9 Number and *class of all *securities not quoted on ASX (including the *securities in section 2 if applicable)

Number +Class
Nil

10 Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)

Rank equally with the existing shares

Part 2 - Pro rata issue

11 Is security holder approval required?

N/A			

12 Is the issue renounceable or non-renounceable?

N/A			

04/03/2013 Appendix 3B Page 3

⁺ See chapter 19 for defined terms.

13	Ratio in which the *securities will be offered	N/A
14	*Class of *securities to which the offer relates	N/A
15	⁺ Record date to determine entitlements	N/A
16	Will holdings on different registers (or sub registers) be aggregated for calculating entitlements?	N/A
17	Policy for deciding entitlements in relation to fractions	N/A
18	Names of countries in which the entity has security holders who will not be sent new offer documents Note: Security holders must be told how their entitlements are to be dealt with. Cross reference: rule 7.7.	N/A
19	Closing date for receipt of acceptances or renunciations	N/A
20	Names of any underwriters	N/A
21	Amount of any underwriting fee or commission	N/A
22	Names of any brokers to the issue	N/A
23	Fee or commission payable to the broker to the issue	N/A
24	Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of security holders	N/A
25	If the issue is contingent on security holders' approval, the date of the meeting	N/A
26	Date entitlement and acceptance form and offer documents will be sent to persons entitled	N/A
27	If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders	N/A

Appendix 3B New issue announcement

28	Date rights trading will begin (if applicable)	N/A
29	Date rights trading will end (if applicable)	N/A
30	How do security holders sell their entitlements in full through a broker?	N/A
31	How do security holders sell <i>part</i> of their entitlements through a broker and accept for the balance?	N/A
32	How do security holders dispose of their entitlements (except by sale through a broker)?	N/A
33	*Issue date	N/A
	3 - Quotation of secu	
You nee	d only complete this section if you are ap	plying for quotation of securities
34	Type of *securities (tick one)	
(a)	*Securities described in Part	1*
(b)		of the escrowed period, partly paid securities that become fully paid, restriction ends, securities issued on expiry or conversion of convertible
Entitio	es that have ticked box 34((a)
Additio	onal securities forming a new c	lass of securities
Tick to docume	indicate you are providing the information	n or
35	1 1	securities, the names of the 20 largest holders of and the number and percentage of additional lers
36		securities, a distribution schedule of the additional nber of holders in the categories

Appendix 3B Page 5 04/03/2013

⁺ See chapter 19 for defined terms.

100	ററ1	and	OVE

	100,001 and 0101		
37	A copy of any trust deed for the	additional *securities	
Entitio	es that have ticked box 34(b)	
38	Number of *securities for which *quotation is sought	N/A	
39	⁺ Class of ⁺ securities for which quotation is sought	N/A	
40	Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities?	N/A	
	If the additional *securities do not rank equally, please state: • the date from which they do • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment		
41	Reason for request for quotation now Example: In the case of restricted securities, end of restriction period (if issued upon conversion of another +security, clearly identify that other +security)	N/A	
42	Number and *class of all *securities quoted on ASX (including the *securities in clause 38)	Number N/A	+Class N/A

Quotation agreement

- [†]Quotation of our additional [†]securities is in ASX's absolute discretion. ASX may quote the [†]securities on any conditions it decides.
- 2 We warrant the following to ASX.
 - The issue of the *securities to be quoted complies with the law and is not for an illegal purpose.
 - There is no reason why those *securities should not be granted *quotation.
 - An offer of the *securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any *securities to be quoted and that no-one has any right to return any *securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the *securities be quoted.
- If we are a trust, we warrant that no person has the right to return the

 †securities to be quoted under section 1019B of the Corporations Act at the
 time that we request that the †securities be quoted.
- We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document is not available now, we will give it to ASX before *quotation of the *securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sophie Karzis Company Secretary 27 April 2018

04/03/2013 Appendix 3B Page 7

⁺ See chapter 19 for defined terms.

Appendix 3B – Annexure 1

Calculation of placement capacity under rule 7.1 and rule 7.1A for eligible entities

Introduced 01/08/12 Amended 04/03/13

Part 1

Rule 7.1 – Issues exceeding 15% of capital Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
Add the following:		
 Number of fully paid +ordinary securities issued in that 12 month period under an exception in rule 7.2 Number of fully paid +ordinary securities issued in that 12 month period with shareholder approval Number of partly paid +ordinary securities that became fully paid in that 12 month period Note: Include only ordinary securities here – other classes of equity securities cannot be added Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed It may be useful to set out issues of securities on different dates as separate line items 	453,984 fully paid ordinary shares issued on 27 October 2017 338,450 fully paid ordinary shares issued on 27 April 2018	
Subtract the number of fully paid +ordinary securities cancelled during that 12 month period	0	
"A"	101,970,381	
Step 2: Calculate 15% of "A"		
"B"	0.15 [Note: this value cannot be changed]	
Multiply "A" by 0.15	15,295,557	

Step 3: Calculate "C", the amount of placement capacity under rule 7.1 that has already been used		
Insert number of +equity securities issued or agreed to be issued in that 12 month period not counting those issued:	584,013 fully paid ordinary shares issued on 1 November 2017	
Under an exception in rule 7.2	258,205 fully paid ordinary shares issued on 19 March 2018	
Under rule 7.1A	19 Watch 2016	
With security holder approval under rule 7.1 or rule 7.4		
 Note: This applies to equity securities, unless specifically excluded – not just ordinary securities Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed It may be useful to set out issues of securities on different dates as separate line items 		
"C"	842,218	
Step 4: Subtract "C" from ["A" x "B"] to calculate remaining placement capacity under rule 7.1		
"A" x 0.15 Note: number must be same as shown in Step 2	15,295,557	
Subtract "C"		
Note: number must be same as shown in Step 3	842,218	
Total ["A" x 0.15] – "C"	14,453,339	
	[Note: this is the remaining placement capacity under rule 7.1]	

o4/o3/2013 Appendix 3B Page 9

⁺ See chapter 19 for defined terms.

Part 2

Rule 7.1A – Additional placement capacity for eligible entities Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
Note: number must be same as shown in Step 1 of Part 1		
Step 2: Calculate 10% of "A"		
"D"	0.10 Note: this value cannot be changed	
Multiply "A" by 0.10		
Step 3: Calculate "E", the amount of placement capacity under rule 7.1A that has already been used		
Insert number of *equity securities issued or agreed to be issued in that 12 month period under rule 7.1A		
 Notes: This applies to equity securities – not just ordinary securities Include here – if applicable – the securities the subject of the Appendix 3B to which this form is annexed Do not include equity securities issued under rule 7.1 (they must be dealt with in Part 1), or for which specific security holder approval has been obtained It may be useful to set out issues of securities on different dates as separate line items 		
"E"		
Step 4: Subtract "E" from ["A" x "D"] to calculate remaining placement capacity under rule 7.1A		
"A" × 0.10		
Note: number must be same as shown in Step 2		
Subtract "E" Note: number must be same as shown in Step 3		
. Total ["A" x 0.10] – "E"	Note: this is the remaining placement capacity under rule 7.1A	